Johnson & Johnson reports positive TREMFYA Phase 4 results in axial psoriatic arthritis

Johnson & Johnson reported on Nov. 20, 2026 that TREMFYA met primary and major secondary endpoints in the Phase 4 STAR study of biologic-naïve adults with active psoriatic arthritis and axial involvement. At Week 24, BASDAI scores improved by −3.3 with 100 mg every four weeks and −2.9 with dosing every eight weeks, versus −2.1 for placebo. MRI-assessed sacroiliac inflammation scores fell by −7.1 and −5.2, respectively, versus −2.4 for placebo, and the company reported no new safety signals.

The results add clinical evidence for TREMFYA in axial psoriatic arthritis, a manifestation with limited dedicated trial data. Johnson & Johnson's release notes that every-four-week dosing is not approved in the U.S., so the findings do not by themselves establish a new U.S. dosing authorization.

  • 1The STAR study evaluated 411 biologic-naïve participants in a randomized, double-blind, placebo-controlled trial.
  • 2At Week 24, mean BASDAI scores improved by −3.3 with TREMFYA 100 mg every four weeks, −2.9 with every-eight-week dosing, and −2.1 with placebo.
  • 3At Week 24, ASDAS-CRP reductions were −1.5 and −1.3 for the two TREMFYA dosing schedules, versus −0.8 for placebo.
  • 4SPARCC MRI scores for sacroiliac-joint inflammation fell by −7.1 with every-four-week dosing and −5.2 with every-eight-week dosing, versus −2.4 with placebo.
  • 5The company said the STAR study showed no new safety signals.

Sources